CIK 0001422143
- Non-accelerated filer
- Smaller reporting company
Kura Oncology, Inc.
Sign in to watch- Ticker
- KURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 611547851
- Phone
- +1 858-500-8800
- Business address
- 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
- Former names
- ZETA ACQUISITION CORP III
- Open-market buys, last 90 days
- $4,248,530
- in 3 filings
- Open-market sales, last 90 days
- $1,929,830
- in 12 filings, $348K under 10b5-1 plans
Net +$2,318,700. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- WILSON TROY EDWARD +$4.2M President and CEO 3 filings
- Leoni Mollie −$747K Chief Medical Officer sold 45% of stake
- Powl Brian T. −$530K Chief Commercial Officer sold 34% of stake
- Burrows Francis −$225K Chief Scientific Officer sold 33% of stake
- FORD KATHLEEN −$192K Chief Operating Officer sold 14% of stake
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-04 | VASCONCELLES MICHAEL Director | Grant or award · Option to purchase common stock | +35,000 | 35,000 | ||
| 2025-06-05 | VASCONCELLES MICHAEL Director | Grant or award · Option to purchase common stock | +28,500 | 28,500 | ||
| 2024-09-13 | VASCONCELLES MICHAEL Director | Grant or award · Option to purchase common stock | +52,000 | 52,000 | ||
| 2024-09-13 | VASCONCELLES MICHAEL Director | Grant or award · Option to purchase common stock | +17,333 | 17,333 |
Page 1 of 1 · 4 trades